Table 3.
Age group specific percentages of participants seroconverting for WHO-recommended influenza strains contained in trivalent study vaccines and geometric mean titers of hemagglutination inhibition antibody at each time point.
| TIV |
aTIV |
||||||
|---|---|---|---|---|---|---|---|
| 6 through | 12 through | 36 through | 6 through | 12 through | 36 through | ||
| 11 months | 35 months | 71 months | 11 months | 35 months | 71 months | ||
| HA dose (volume) | 15 µg | 15 µg | 15 µg | 7.5 µg + MF59 | 7.5 µg + MF59 | 15 µg + MF59 | |
| (0.5 ml) | (0.5 ml) | (0.5 ml) | (0.25 ml) | (0.25 ml) | (0.5 ml) | ||
| N = 26 | N = 34 | N = 33 | N = 30 | N = 31 | N = 38 | ||
| A/California (H1N1) | |||||||
| GMT (95% CI) | Baseline | 5.0 (5.0–5.0) | 6.3 (4.8–8.5) | 16.1 (10.0–25.8) | 6.5 (4.9–8.6) | 6.4 (4.8–8.4) | 23.4 (14.7–37.3) |
| 28d post dose 1 | 8.1 (6.3–10.4) | 19.2 (11.3–32.6) | 115.1 (58.0–228.5) | 51.6 (35.0–76.1) | 83.7 (49.1–142.5) | 501.8 (282.9–889.9) | |
| 28d post dose 2 | 49.2 (33.3–72.9) | 115.4 (83.8–159.1) | 194.6 (135.3–279.8) | 221.1 (160.0–305.5) | 209.2 (153.8–284.7) | 492.9 (347.1–699.7) | |
| GMT ratio from | 28d post dose 1 | 1.6 (1.3–2.1) | 3.0 (2.2–4.2) | 7.2 (4.8–10.6) | 7.9 (5.3–12.0) | 13.2 (9.4–18.5) | 21.4 (15.6–29.5) |
| baseline | 28d post dose 2 | 9.8 (6.6–14.6) | 18.2 (14.1–23.5) | 12.1 (9.2–15.8) | 34.0 (25.4–45.5) | 33.0 (25.6–42.5) | 21.0 (15.9–27.8) |
| A/Victoria (H3N2) | |||||||
| GMT (95% CI) | Baseline | 11.2 (5.9–21.2) | 68.4 (39.5–118.6) | 71.0 (39.9–126.5) | 24.6 (12.0–50.6) | 47.1 (22.8–97.6) | 123.9 (80.1–191.8) |
| 28d post dose 1 | 50.9 (22.0–117.5) | 784.7 (416.5–1478.5) | 507.8 (273.8–942.1) | 246.2 (107.7–562.4) | 519.5 (239.7–1125.9) | 1295.7 (866.9–1936.5) | |
| 28d post dose 2 | 220.3 (125.7–386.2) | 1022.8 (733.6–1426.1) | 762.4 (536.3–1083.9) | 831.6 (547.7–1262.6) | 950.0 (649.4–1389.8) | 1256.9 (990.9–1594.3) | |
| GMT ratio | 28d post dose 1 | 4.5 (3.1–6.6) | 11.5 (8.1–16.3) | 7.2 (4.4–11.8) | 10.0 (5.4–18.5) | 11.0 (8.1–15.0) | 10.5 (8.3–13.2) |
| from baseline | 28d post dose 2 | 19.6 (14.2–27.1) | 14.9 (10.1–22.2) | 10.7 (7.2–16.0) | 33.8 (20.9–54.5) | 20.2 (13.1–30.9) | 10.1 (7.0–14.7) |
| B/Wisconsin | |||||||
| (Yamagata lineage) | |||||||
| GMT (95% CI) | Baseline | 18.7 (11.6–30.1) | 19.7 (12.6–30.9) | 26.7 (15.5–45.8) | 13.1 (9.1–19.0) | 20.9 (12.4–35.5) | 28.5 (18.7–43.3) |
| 28d post dose 1 | 23.1 (13.3–40.2) | 45.0 (25.2–80.4) | 96.9 (47.4–198.0) | 52.4 (33.3–82.5) | 94.5 (47.6–187.6) | 136.6 (74.0–252.3) | |
| 28d post dose 2 | 100.8 (64.3–158.1) | 212.9 (143.6–315.7) | 257.5 (174.9–379.0) | 500.2 (397.5–629.5) | 457.6 (358.7–583.8) | 431.1 (333.8–556.7) | |
| GMT ratio | 28d post dose 1 | 1.2 (0.7–2.2) | 2.3 (1.2–4.4) | 3.6 (1.9–6.9) | 4.0 (2.9–5.6) | 4.5 (2.3–8.7) | 4.8 (2.7–8.7) |
| from baseline | 28d post dose 2 | 5.4 (3.4–8.5) | 10.8 (6.2–18.9) | 9.7 (5.8–16.0) | 38.2 (27.7–52.6) | 21.9 (12.9–37.0) | 15.1 (10.1–22.8) |